Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/10.3389/fimmu.2021.800968
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Alfaro, Rafael | - |
dc.contributor.author | Martínez Banaclocha, Helios | - |
dc.contributor.author | Llorente, Santiago | - |
dc.contributor.author | Jiménez Coll, Víctor | - |
dc.contributor.author | Galián, José Antonio | - |
dc.contributor.author | Botella, Carmen | - |
dc.contributor.author | Moya Quiles, María Rosa | - |
dc.contributor.author | Parrado, Antonio | - |
dc.contributor.author | Muro Pérez, Manuel | - |
dc.contributor.author | Minguela, Alfredo | - |
dc.contributor.author | Legaz Pérez, Isabel | - |
dc.contributor.author | Muro, Manuel | - |
dc.contributor.other | Facultades, Departamentos, Servicios y Escuelas::Departamentos de la UMU::Ciencias Sociosanitarias | - |
dc.date.accessioned | 2024-07-11T10:52:05Z | - |
dc.date.available | 2024-07-11T10:52:05Z | - |
dc.date.issued | 2021-12-15 | - |
dc.identifier.citation | Front. Immunol. 12:800968 | es |
dc.identifier.issn | Electronic: 1664-3224 | - |
dc.identifier.uri | http://hdl.handle.net/10201/143010 | - |
dc.description | © 2021 Alfaro, Martınez-Banaclocha, Llorente, Jimenez-Coll, Galián, Botella, Moya-Quiles, Parrado, Muro-Perez, Minguela, Legaz and Muro. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/. This document is the Published version of a Published Work that appeared in final form in Frontiers in Immunology. To access the final edited and published work see https://doi.org/10.3389/fimmu.2021.800968 | - |
dc.description.abstract | Background: The diagnosis of graft rejection in kidney transplantation (KT) patients is made by evaluating the histological characteristics of biopsy samples. The evolution of omics sciences and bioinformatics techniques has contributed to the advancement in searching and predicting biomarkers, pathways, and new target drugs that allow a more precise and less invasive diagnosis. The aim was to search for differentially expressed genes (DEGs) in patients with/without antibody-mediated rejection (AMR) and find essential cells involved in AMR, new target drugs, protein-protein interactions (PPI), and know their functional and biological analysis. Material and Methods: Four GEO databases of kidney biopsies of kidney transplantation with/without AMR were analyzed. The infiltrating leukocyte populations in the graft, new target drugs, protein-protein interactions (PPI), functional and biological analysis were studied by different bioinformatics tools. Results: Our results show DEGs and the infiltrating leukocyte populations in the graft. There is an increase in the expression of genes related to different stages of the activation of the immune system, antigenic presentation such as antibody-mediated cytotoxicity, or leukocyte migration during AMR. The importance of the IRF/STAT1 pathways of response to IFN in controlling the expression of genes related to humoral rejection. The genes of this biological pathway were postulated as potential therapeutic targets and biomarkers of AMR. These biological processes correlated showed the infiltration of NK cells and monocytes towards the allograft. Besides the increase in dendritic cell maturation, it plays a central role in mediating the damage suffered by the graft during AMR. Computational approaches to the search for new therapeutic uses of approved target drugs also showed that imatinib might theoretically be helpful in KT for the prevention and/or treatment of AMR. Conclusion: Our results suggest the importance of the IRF/STAT1 pathways in humoral kidney rejection. NK cells and monocytes in graft damage have an essential role during rejection, and imatinib improves KT outcomes. Our results will have to be validated for the potential use of overexpressed genes as rejection biomarkers that can be used as diagnostic and prognostic markers and as therapeutic targets to avoid graft rejection in patients undergoing kidney transplantation. | es |
dc.format | application/pdf | es |
dc.format.extent | 21 | es |
dc.language | eng | es |
dc.publisher | Frontiers Media | - |
dc.relation | Our work was possible thanks to support from Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness. Grant Number PI15/01370, P19/01194, and PI20/00050 and co-funding the European Union with the European Fund of Regional Development (FEDER) with the principle of “A manner to build Europe” | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Bioinformatics tool | es |
dc.subject | Biomarkers | es |
dc.subject | Acute rejection | es |
dc.subject | Kidney transplant | es |
dc.subject | New target drugs | es |
dc.title | Computational prediction of biomarkers, pathways, and new target drugs in the pathogenesis of immune-based diseases regarding kidney transplantation rejection | es |
dc.type | info:eu-repo/semantics/article | es |
dc.relation.publisherversion | https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.800968/full | - |
dc.identifier.doi | https://doi.org/10.3389/fimmu.2021.800968 | - |
Aparece en las colecciones: | Artículos: Ciencias Sociosanitarias |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
fimmu-12-800968.pdf | 62,98 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons